Tea Symposium 14 October 2016, 10:30am
Sponsored by Genomic Health
Topic : Genomic Assays in Breast Cancer: "Great Expectations" or "Risky Business"?
Speaker: David M Hyams MD, FACS
Better risk stratification of patients with early stage breast cancer may identify individuals who do not benefit from adjuvant chemotherapy. Multi-gene risk classifiers produce the “great expectation” of rational adjuvant therapy decision-making. Commercially available multigene breast cancer classifiers, as well as their associated clinical validation and clinical utility studies, will be presented. Only two tests, Oncotype DX and Mammaprint have any purely prospective supportive data. Oncotype DX has Level I evidence for postoperative adjuvant treatment derived from 2 separate randomized trials with comparative treatment arms. Both studies support the value of Oncotype DX in predicting postoperative adjuvant chemotherapy response in a broad population of patients with hormone receptor-positive, lymph node-negative and lymph node-positive early stage breast cancer. The “great expectation” of breast cancer gene expression assays is well justified when an individual test is carefully selected. However, the use of inadequately validated genomic classifiers may threaten patient survival and become a very “risky business”.
About the speaker :
Dr Hyams received his undergraduate degree from Vassar College and his Doctor of Medicine from Columbia University. Dr Hyams directed Surgical Oncology at the University of Cincinnati and has served on the faculty of Allegheny University of the Health Sciences in Pittsburgh. A long-time investigator with the NSABP, he was the group’s Executive Medical Officer and Director of Medical Affairs. Currently, Dr Hyams is Director of Desert Surgical Oncology at Eisenhower Medical Center in Southern California, USA. He has had a clinical focus on breast cancer, melanoma, and soft tissue malignancies. Oncoplastic procedures, including breast reconstruction, are an important part of his practice and educational activity.
Lunch Symposium 14 October 2016, 12:45pm
Sponsored by Pfizer
Topic : Endocrine Therapy Updates in Metastatic Breast Cancer
Speaker: Dr Senthil J Rajappa, DM
Hormone receptor positive breast cancer represents the most common sub-type of breast cancer. Endocrine therapy (ET) is highly effective in this subgroup. Better understanding of biology has led to multiple therapies and improved outcomes in metastatic breast cancer. However, resistance to endocrine therapy remains a challenge. In the recent years, there has been a lot of interest in combining ET with targeted therapy but there are also considerations for toxicity, cost and quality of life issues. The talk will update on what is the best way to use all agents available.
About the speaker:
Dr Rajappa is a Head of Department and Senior Consultant of the Department of Medical Oncology at theBasavatarakam Indo American Cancer Hospitaland Research Institute in Hyderabad, India. He received his Diplomate of National Board (Internal Medicine) from the National Board of Examinations, New Delhi in 1999 and is the author of several oncological papers.
Dinner Symposium 13 October 2016, 7:00pm
Sponsored by GE HealthCare
1st Talk: Senographe Pristina: Innovations designed for “Reshaping the Mammography Experience For Patients, Technologists And Radiologists
Speaker: Emilie Rouaud, GE Global Marketing Manager
2nd Talk : How To Set Up A Contrast-enhanced Spectral Mammography Service - The Cambridge Experience
Speaker: Dr Penny Moyle MBChB (Hons) , MRCP, FRCR
Dr Moyle's specialist interest is in women's imaging which includes breast and gynaecological imaging. She has written several book chapters and peer review articles on gynaecological cancer imaging and also breast oncology.She is involved in the UK national POSH study, CONTEND CESM study, breast Tomosynthesis I specimen x-rays, and interval cancer review. She is on the panel of experts to review the Royal College of Radiologists imaging guidelines 2016 and has given lectures in both gynaecological imaging and breast imaging nationally (Oxford MRI course tutorials, Cambridge Breast Conference 2014), and in Tokyo and Kyoto in 2016.